ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ニフルチモックス

Nifurtimox

HCID 6842999
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
23256-30-6
標準SMILES
CC1CS(=O)(=O)CCN1/N=C/c1ccc([N+](=O)[O-])o1
InChIKey
ARFHIAQFJWUCFH-IZZDOVSWSA-N
分子式
C10H13N3O5S
平均分子量
287.29 g/mol
単同位体質量
287.0575917

概要

Nifurtimox is a nitrofuran antibiotic.

名称と識別子

優先名称
Nifurtimox
IUPAC
(E)-N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine
現地名
ニフルチモックス
英語名
nifurtimox
分子式
C10H13N3O5S
分子量
287.29

名称と別名

NIFURTIMOX23256-30-6LampitBayer 2502BAY 2502NifurtimoxumBAYER-2502BAY A2502BAY-A2502BAY-2502DNDI1613515M84I3K7C2O
名称をさらに表示
4-[(5-ニトロフルフリリデン)アミノ]-3-メチルチオモルホリン1,1-ジオキシド4-[[(5-ニトロ-2-フラニル)メチレン]アミノ]-3-メチルチオモルホリン1,1-ジオキシド3-メチル-N-[(5-ニトロ-2-フラニル)メチレン]-4-チオモルホリンアミン1,1-ジオキシドランピットニフルチモックスニフルチモクス4-(5-ニトロフルフリリデンアミノ)-3-メチルテトラヒドロ-2H-1,4-チアジン1,1-ジオキシド3-メチル-4-{[(5-ニトロフラン-2-イル)メチリデン]アミノ}チオモルホリン-1,1-ジイウム-1,1-ビス(オラート)NIFURIMOXAids007325BAY-A-2502Aids-007325(±)-Nifurtimox
DTXCID10254394-Thiomorpholinamine, 3-methyl-N-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide4-Thiomorpholinamine, 3-methyl-N-[(5-nitro-2-furanyl)methylene]-, 1,1-dioxide4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxideThiomorpholine, 3-methyl-4-((5-nitrofurfurylidene)amino)-, 1,1-dioxideN-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimineDTXSID30454393-methyl-4-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1lambda6-thiomorpholine-1,1-dione

データベース識別子

CAS
23256-30-6、39072-15-6、39072-16-7
PubChem CID
6842999
DTXSID
DTXSID201369277
ChEMBL
CHEMBL290960
ChEBI
CHEBI:7566
UNII
M84I3K7C2O
EC Number
245-531-0

物性

構造計算による物性補完中

XLogP
1.3
極性表面積
117 Ų
水素結合供与体数
0
水素結合受容体数
7
回転可能結合数
2
重原子数
19
形式電荷
0
複雑度
467

実験および物理化学的性質

Human Drugs · 4 件

Breast Feeding; Lactation; Antiprotozoal Agents; Nitrofurans; Trypanocidal Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

American trypanosomiasis

Boiling Point550.3±50.0
Melting Point177-183
Dissociation Constants-1.01±0.40

物理化学的性質

融点
177 · 177-183°C
沸点
550.3 · 550.3±50.0 °C(Predicted)
比重(密度)
1.4716 · 1.4716 (rough estimate)
屈折率
1.639 · 1.6390 (estimate)
貯蔵温度
room temp
溶解性
13 mg/mL以上 · DMSO:13mg/mL以上
外見
粉
酸解離定数(Pka)
-1.01 · -1.01±0.40(Predicted)
色
黄色からオレンジ
水溶解度
33 g/L · 33g/L(温度表記なし)
BCS Class
3 · 3
InChI
1S/C10H13N3O5S/c1-8-7-19(16,17)5-4-12(8)11-6-9-2-3-10(18-9)13(14)15/h2-3,6,8H,4-5,7H2,1H3/b11-6+
InChIKey
ARFHIAQFJWUCFH-IZZDOVSWSA-N
SMILES
CC1CS(=O)(=O)CCN1\N=C\c2ccc(o2)[N+]([O-])=O

化学的性質

化学的特性Orange Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H373 (100%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

P260, P319, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 24 reports by companies from 1 notifications to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesSTOT RE 2 (100%)

毒性情報

Hepatotoxicity · 1 件

In multiple prospective controlled trials, nifurtimox therapy was not associated with elevations in aminotransferase or bilirubin levels or with instances of clinically apparent liver injury. Since approval of nifurtimox for American trypanosomiasis, there have been no individual reports of liver injury associated with its use.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Nifurtimox

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
毒性
LD50 in mice, rats (mg/kg): 3720, 4050 by gavage (Hoffmann)
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 3 件

P - Antiparasitic products, insecticides and repellents

QP - Antiparasitic products, insecticides and repellents

P01CC01

Protein BindingThe plasma protein binding of nifurtimox is approximately 42%. It is primarily bound to albumin.
Pharmacodynamics · 1 件

Nifurtimox exerts trypanosomal activity against Trypanosoma cruzi, treating Chagas disease. One study reports that nifurtimox and other benzofuran derivatives reduce parasite dehydrogenase activity. Results of a recent phase III clinical trial have shown that a significant number of pediatric patients with acute or chronic Chagas disease treated with nifurtimox were immunoglobulin G (IgG) antibody negative and demonstrated at least a 20% decrease in optical density on two IgG antibody tests for T. cruzi antigens.

Mechanism of Action · 1 件

The mechanism of action of nifurtimox has not been fully elucidated, however, is believed to occur by the activation of nitroreductase enzymes that produce reactive metabolites with a series of deleterious effects on Trypanosoma cruzi, the parasite causing Chagas disease. The antiprotozoal actions of nifurtimox occur both intracellularly and extracellularly. Inhibition of parasite dehydrogenase activity is another purported mode of action of nifurtimox that warrants further research.

Biological Half-LifeThe elimination half-life of nifurtimox ranges from 2.4–3.6 hours. A pharmacokinetic study of healthy volunteers and patients with renal failure revealed respective mean half-lives of 2.95 h and 3.95 h.
Metabolism/Metabolites · 1 件

Nifurtimox is largely metabolized via nitroreductase enzymes. Two major inactive metabolites have been identified: M-4 and M-6. The M-4 metabolite is a cysteine conjugate of nifurtimox, while M-6 is likely formed by hydrolytic cleavage of the hydrazone moiety of nifurtimox. Other minor metabolites have also been identified in human plasma.

MeSH Pharmacological ClassificationAgents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA.
Absorption, Distribution and Excretion · 4 件

The average AUC of nifurtimox is estimated between 1676-2670 μg∙h/L. One pharmacokinetic study of healthy volunteers revealed an AUC of 5430 ng∙ml-1∙h. Cmax ranges between 425-568 μg/L (26–50%) after a single dose of 20 mg with food in adults. Tmax is 4 hours, ranging from 2 to 8 hours post-dose in the fed state. In a pharmacokinetic study of healthy volunteers, serum concentration was low, likely due to the first-pass effect.

In the fed state, 44% of the dose was mainly recovered in the urine as metabolites. Fecal and biliary excretion of nifurtimox have not been studied.

Nifurtimox crosses the blood-brain barrier and the placenta.

One pharmacokinetic study of nifurtimox revealed a clearance of 193.4 l∙h<sup>-1</sup>. In patients without renal failure; clearance was 99.7 l∙h<sup>-1</sup>.

応用分野 · 3 件

説明Nifurtimox is manufactured by Bayer and marketed under the trade name Lampits.It is a nitrofuran derivative that was developed specifically for the treatment of American trypanosomiasis (Chagas'disease) (Packachanian, 1957). Nifurtimox is one of two drugs approved for use in treatment of Chagasdisease. It was shown to be the most active and least toxic of this group of agents in preclinical studies and was evaluated in clinical trials in the 1960s and subsequently marketed for use in Chagas’ disease in Latin America in the late 1960s and early 1970s. Although the use of nifurtimox for Chagas’ disease has decreased with the availability of benznidazole, a potentially more active and less toxic agent, there has been a resurgence of interest in and use of nifurtimox for the treatment of second-stage human African trypanosomiasis (HAT)caused by Trypanosoma brucei gambiense.

使用Antiprotozoal (Trypanosoma). Showing anti-Trypanosoma cruzi activity.

一般的な説明Nifurtimox acts as a hypoxia-activated cytotoxin, which specifically kills clonogenic tumor cells under hypoxic conditions. It is used to treat Chagas disease and African trypanosomiasis. Nifurtimox inhibits neuroblastoma and medulloblastoma cell growth.

関連反応

2 件
反応記録を作成
HRID 633786 の反応式
HRID 633786反応物として
HRID 1618914 の反応式
HRID 1618914反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート